Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Related GHDX
Benzinga's Top Upgrades
Genomic Health: A Prostate Play Helping Investors Get Ahead Of The Curve?

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Latest Ratings for GHDX

Nov 2015UBSUpgradesNeutralBuy
Nov 2015Cowen & CompanyUpgradesMarket PerformOutperform
Nov 2015Raymond JamesUpgradesMarket PerformOutperform

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (GHDX)

Get Benzinga's Newsletters